Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial

https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(23)00376-4/fulltext?dgcid=hubspot_email_covidalerts&utm_campaign=lancetcovid22&utm_medium=email&_hsmi=283901121&_hsenc=p2ANqtz-9EdYmC3v7JPqcOA1cfH24G_6u8Uglpi8YI1yNRZFchOSUNnO-I6j_pjg_N2bzBKWgYyIGy8HRLHMxi3yWDsp1-MPb21g&utm_content=283899141&utm_source=hs_email